BioCentury
ARTICLE | Clinical News

Aronex reports Phase II Atragen data in NHL

December 4, 2000 8:00 AM UTC

ARNX said that in an ongoing Phase II study of its Atragen injectable liposomal all-trans retinoic acid to treat relapsed or refractory non-Hodgkin's lymphoma (NHL) and cutaneous T cell lymphoma, 17 o...